LIQTECH INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIQTECH INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $250.9K | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.78M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $567.1K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.58M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.15M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.16M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.07M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $206.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.43M | Mar 23, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.53M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($10.35M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.57M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($14.17M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($11.13M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($9.81M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $39.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.81M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.46M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($16.42M) | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.31M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.49M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($7.80M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($12.53M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($10.69M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.26M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($577.1K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($4.49M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.61M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($13.13M) | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.35M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.42M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.84M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.86M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.28M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $749.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $661.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $536.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $626.1K | Mar 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.11M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($7.53M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($4.18M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($12.04M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($7.20M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($2.60M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.55M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.91M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.32M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $415.8K | Mar 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $395.2K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.37M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.89M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.69M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.13M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.75M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.54M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $178.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $137.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $373.7K | Mar 23, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.28M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $32.43M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $35.97M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $40.13M | Mar 22, 2024 |
| FY2022 | Sep 30, 2022 | $40.13M | Mar 22, 2023 |
| FY2022 | Dec 31, 2021 | $45.05M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $42.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $38.59M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.16M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.68M | Apr 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $15.77M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $18.70M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $16.82M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $32.28M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $17.39M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.58M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.62M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.77M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.14M | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.65M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $17.28M | Mar 28, 2025 |
| FY2024 | Dec 31, 2022 | $23.31M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $12.77M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $24.82M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $23.01M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $8.54M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $6.91M | Mar 30, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.1K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $220.7K | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $233.7K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $226.1K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $240.3K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $260.2K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $236.1K | Mar 31, 2021 |
| FY2016 | Dec 31, 2015 | $7.58M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $8.46M | Mar 23, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.80M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($86.27M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($75.92M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($67.35M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($53.18M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($42.05M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($32.25M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($32.29M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($28.47M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($24.01M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07M | Feb 27, 2026 |
| FY2023 | Dec 31, 2023 | $10.42M | Mar 22, 2024 |
| FY2021 | Dec 31, 2021 | $15.36M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $11.75M | Mar 31, 2022 |
| FY2020 | Sep 30, 2020 | $11.75M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $7.07M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.78M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.49M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $1.21M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $1.37M | Mar 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 25, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Mar 27, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.63M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 9.48M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 5.73M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 5.50M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 21.29M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 21.66M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 20.55M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 18.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 44.23M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 36.84M | Mar 23, 2018 |